Tempus HRD in the marketplace:

Question 1

Claims to avoid, know what NOT to say:

Answer 1

• Do not claim any association of Tempus HRD to therapies.
• we can’t link these indications to the HRD test result directly.
• Do not claim any comparison/association of Tempus HRD with our competitors.
• Don’t claim an association with clinical trials or enrollment.
• Don’t claim any association of a specific gene expressoin as a driver of our HRD RNA algorithm.
• Don’t claim that HRD is two test. It’s a single test.

Question 2

1)

Answer 2

Genomic defects in the HRR pathway can drive the development of cancers, and cancers with the inability to repair DNA via the HRR pathway are said to have homologous recombination deficiency (HRD)

Question 3

2)

Answer 3

There are multiple ways to analyze a tumor for HRD, including examining genome-wide loss of heterozygosity and determining an RNA expression score.

Question 4

3)

Answer 4

The Tempus HRD test combines analysis of 23 HRR genes and a proprietary genome-wide LOH score for breast and ovarian cancers, or an RNA expression score for other cancer types.

Question 5

4)

Answer 5

Messaging of the HRD test focuses on the identification of the HRD molecular phenotype, rather than on making claims associated with therapeutic or clinical trial matching.

Question 6

5)

Answer 6

The addition of HRD to xT is another example of the board-based panel testing that doesn’t require another tumor sample.